Harvoni vs Mavyret

Listen to the article instead of reading through it.

--:--

Introduction

For patients with chronic hepatitis c (HCV), certain antiviral medications that inhibit the replication of HCV RNA in host cells can help achieve sustained virologic response, effectively curing the disease. Harvoni and Mavyret are two such drugs that are prescribed for this purpose. They each target different stages of the viral life cycle but both have been shown to be highly effective treatments for people with HCV infection. Harvoni is a combination pill containing ledipasvir, a NS5A inhibitor, and sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor; it primarily interferes with the proteins necessary for virus reproduction. On the other hand, Mavyret is composed of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor; it blocks both protein processing and viral assembly/release.

What is Harvoni?

Harvoni and Mavyret are both breakthrough drugs in the treatment of Hepatitis c, a disease that affects the liver. Harvoni, which consists of ledipasvir and sofosbuvir, was first approved by the FDA in 2014. This drug works by blocking a protein that the hepatitis C virus needs to reproduce, effectively halting its spread within the body. It is prescribed for different genotypes of Hepatitis C.

On other hand, Mavyret (glecaprevir/pibrentasvir) is used for all six major forms of Hepatitis C and was approved by FDA later in 2017. Unlike Harvoni which requires up to 12 weeks regimen for some patients based on their liver condition or prior treatments, Mavyret can cure patients with most types of HCV infection within an eight-week course regardless of cirrhosis status or previous treatments.

Both have proven highly effective at curing various types Hepatitis C but potential side effects differ between these two medications. While fatigue and headache are common with Harvoni; nausea, stomach pain and fatigue may occur with Mavyret.

What conditions is Harvoni approved to treat?

Harvoni and Mavyret are approved by the FDA for the treatment of different forms of hepatitis c:

Harvoni is used to treat chronic hepatitis C genotypes 1, 4, 5, and 6 in adults. It can also be used in combination with ribavirin for certain patient populations.
Mavyret is prescribed to adult patients suffering from chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with compensated cirrhosis. It can also be administered to patients who have HCV genotype 1 infection and have previously been treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both.

How does Harvoni help with these illnesses?

Harvoni aids in the management of Hepatitis c by disrupting the virus's ability to multiply. It does this by blocking an enzyme called NS5A, which is crucial for the replication of the Hepatitis C virus within liver cells, thereby preventing its spread throughout the body. The Hepatitis C virus is a bloodborne pathogen that primarily affects liver function and can lead to severe health complications such as cirrhosis or liver cancer if left untreated. Individuals suffering from chronic hepatitis C often carry high levels of this virus in their bodies. By reducing viral replication, Harvoni helps limit damage to the liver and manage patient conditions effectively.

Mavyret also works similarly as it blocks not only NS5A but another enzyme known as NS3/4A protease inhibitor involved in viral replication, providing a two-pronged attack on controlling the disease progression.

What is Mavyret?

Mavyret is a brand name for a combination of glecaprevir and pibrentasvir, which are direct-acting antiviral agents that work by inhibiting the proteins needed by Hepatitis c virus (HCV) to multiply. This results in stopping the virus from reproducing and decreasing its presence in your body. Mavyret was first approved by the FDA in 2017. As it's not just one type of drug but rather a combination, it can be used to treat all six major forms of HCV. Its broad-spectrum nature means that its therapeutic profile is different than other treatments such as Harvoni (ledipasvir/sofosbuvir). Unlike Harvoni, Mavyret requires a shorter treatment duration - typically 8 weeks compared to 12 or even up to 24 weeks with Harvoni. Side effects may include headache, fatigue, and nausea but these are generally considered mild and manageable especially when considering its benefits for patients suffering from HCV including those who did not have success with previous treatments.

What conditions is Mavyret approved to treat?

Mavyret is a powerful medication approved for the treatment of:

Chronic hepatitis c virus (HCV) genotypes 1-6 in adults and pediatric patients aged 12 years and older or weighing at least 45 kg without cirrhosis or with compensated cirrhosis.
HCV genotype 1 infection in adults who have been previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

How does Mavyret help with these illnesses?

Mavyret, like Harvoni, is a medication used in the treatment of chronic hepatitis c. It works by inhibiting the enzymes that the virus requires to multiply, thus preventing it from spreading within the body. Mavyret has a broad-spectrum activity and can be used for all genotypes (1-6) of Hepatitis C virus, which gives it an advantage over many other treatments, including Harvoni which is mainly effective against genotype 1. Another key difference between these two medications lies in their treatment durations; while Harvoni typically requires a 12-week course for most patients, Mavyret offers shorter courses with comparable cure rates - usually just eight weeks. This could mean less time dealing with potential side effects and drug interactions for patients on Mavyret.

How effective are both Harvoni and Mavyret?

Both Harvoni and Mavyret are effective antiviral medications with proven histories of success in treating patients with chronic hepatitis c infection. They were approved by the FDA just a few years apart, Harvoni in 2014 and Mavyret in 2017. Because they act on different stages of the virus life cycle, they may be prescribed under different circumstances. In clinical trials for both drugs, high cure rates (sustained virologic response) were observed across various genotypes and patient populations, including those with compensated cirrhosis and HIV co-infection.

A review article published in 2016 highlighted that ledipasvir/sofosbuvir (Harvoni) was highly effective at curing hepatitis C infection within 12 weeks of treatment. Its side effect profile is generally mild, making it well-tolerated among most patient populations including those with kidney disease or liver transplant recipients. It has become one of the most widely used direct-acting antivirals globally due to its efficacy and tolerability.

On the other hand, glecaprevir/pibrentasvir (Mavyret) stands out because it can effectively treat all six major HCV genotypes within an even shorter duration – only eight weeks for patients without cirrhosis who have not previously been treated. This makes it a particularly attractive option where speed is important such as in cases to prevent further liver damage or before transplantation surgery.

While both medications are leading choices for hepatitis C treatment today due to their high efficacy rates and low side effects profiles, choosing between Harvoni and Mavyret often comes down to individual factors such as genotype specificity, presence of any resistance-associated substitutions which might affect drug effectiveness, comorbidities like HIV co-infection or renal disease that might affect drug choice as well as insurance coverage since these drugs come at a significant cost.

abstract image of a researcher studying a bottle of drug.

At what dose is Harvoni typically prescribed?

The recommended regimen for Harvoni is one tablet (90 mg ledipasvir/400 mg sofosbuvir) taken orally once daily with or without food. The duration of treatment varies from 8 to 24 weeks depending on the patient's Hepatitis c genotype, prior treatment history, and presence of cirrhosis. On the other hand, Mavyret comprises a combination pill containing 100mg glecaprevir and 40mg pibrentasvir, typically administered as three tablets once daily with food for an overall course ranging from 8 to 16 weeks based on similar factors such as genotype and liver disease state. For both medications, dosages should be strictly followed under medical supervision due to their potent antiviral effects and potential side effects.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Mavyret typically prescribed?

Mavyret treatment typically begins with a dosage of three tablets (each containing 100mg glecaprevir and 40mg pibrentasvir) taken once daily. This should be done with food, as it aids in the absorption of the drug. The duration of therapy depends largely upon your previous hepatitis c treatments and genotype: for those without cirrhosis or with compensated cirrhosis who are new to treatment, an eight-week course is usually sufficient. For all other patient groups, including those who have previously been treated with certain medications, the recommended period is generally 12-16 weeks. As always, modifications to this regimen should only be made under the supervision of a healthcare provider experienced in treating hepatitis C.

What are the most common side effects for Harvoni?

Common side effects of Harvoni include:

Fatigue
Headache
Nausea
Diarrhea
Insomnia (difficulty sleeping)

As for Mavyret, the potential side effects can be quite similar with some differences. These may include:

Headache
Fatigue
Nausea
Itching or skin rash
Weakness (asthenia)

It's important to remember that these are not all the possible side effects and individual reactions can vary greatly.

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Harvoni?

While both Harvoni and Mavyret are effective treatments for Hepatitis c, they each carry potential side effects. When taking these medications, it's important to watch out for the following:

Allergic reactions: Though rare, some individuals may experience severe allergic reactions that can include hives, difficulty breathing or swallowing, facial swelling or throat tightness.
Unusual weakness or fatigue: If you're feeling excessively tired all of a sudden without any apparent reason, this could be a sign of low red blood cell count (anemia), which is one of the possible side effects associated with these drugs.
Mental changes: Though not common with these medications specifically but as antivirals in general; symptoms like confusion or depression should be monitored closely. In extreme cases there might even be thoughts about suicide or self-harm.
Heart issues: Fast heartbeats, chest pain or palpitations can happen due to certain drug interactions while on this medication
Vision problems: Blurry vision and seeing halos around lights are also reported rarely.
Signs of liver damage - abdominal pain on your upper right side along with loss of appetite and jaundice (yellowing in your eyes and skin)

If any such symptoms present themselves during treatment course contact healthcare provider immediately.

What are the most common side effects for Mavyret?

When comparing Harvoni to Mavyret, one needs to note the potential side effects of Mavyret. These can include:

Nausea and vomiting
Headache
Fatigue or weakness
Abdominal pain
Diarrhea
Itching or rash
Difficulty sleeping (insomnia)
While these symptoms may seem alarming, it's important to remember that not everyone who takes Mavyret will experience these side effects. Additionally, most patients find them manageable with appropriate support and guidance from their healthcare provider.

Are there any potential serious side effects for Mavyret?

While Mavyret is generally well-tolerated, there are some potential side effects that could be serious:

Indications of an allergic reaction may include hives, difficulty breathing or swallowing, swelling in your face or throat
Severe right upper stomach pain or tenderness which might suggest a liver problem
Yellowing of the skin or eyes (jaundice), potentially signaling liver damage
Signs of new onset or worsening heart failure such as shortness of breath, swelling in the feet, ankles and legs, feeling tired and weak; sudden weight gain
If you have ever had Hepatitis b virus infection before starting treatment with Mavyret it could become active again during or after treatment causing serious liver problems including liver failure.

Always consult with your healthcare provider immediately if any troubling symptoms occur while using Mavyret.

Contraindications for Harvoni and Mavyret?

Both Harvoni and Mavyret, along with most other antiviral medications, can cause side effects in some people. If you notice your symptoms worsening, or an increase in fatigue, weakness or confusion, please seek immediate medical attention.

Neither Harvoni nor Mavyret should be taken if you are taking, or have been taking rifampin (a strong antibiotic) due to potential drug interactions that may reduce their effectiveness. Always inform your physician of any medication you are currently on; if you have been on rifampin treatment it will require a period of about 2 weeks to clear from the system before starting therapy with either Harvoni or Mavyret.

Also important is the need for regular liver function tests while taking these drugs particularly in patients with history of liver disease as both medications might exacerbate pre-existing hepatic conditions.

How much do Harvoni and Mavyret cost?

For the brand name versions of these drugs:

The price for a 28 tablet pack of Harvoni (90/400 mg) averages around $31,500, which works out to about $1125/day based on the standard daily dose.
The price for a 8-week supply of Mavyret (100/40 mg) is approximately $26,400 or roughly $375/day.

Thus, if you are comparing costs alone and not considering other factors such as efficacy and patient tolerance, Mavyret may be less expensive than Harvoni. However, it's important to note that cost should not be a primary consideration in determining which drug regimen is right for you.

As of now there are no generic versions available for either Harvoni or Mavyret in most countries including the U.S., however prices can vary greatly depending on insurance coverage and patient assistance programs offered by manufacturers. Always consult your healthcare provider to understand all the benefits and risks associated with each treatment option.

Popularity of Harvoni and Mavyret

Harvoni, a fixed-dose combination medication used for the treatment of Hepatitis c (HCV), was estimated to have been prescribed to about 2.1 million people in the US in 2020. Harvoni accounted for just over 20% of HCV prescriptions in the US, which can be attributed to its high efficacy and safety profile.

Mavyret, another fixed-dose combination medication that treats HCV, has gained traction since getting FDA approval in August 2017. In terms of patient numbers, Mavyret had approximately half as many users as Harvoni did during the same period; however, this number is increasing rapidly due to its lower cost and shorter duration of therapy compared with other available treatments.

The prevalence of both medications reflects their importance in managing hepatitis C infections - a disease which affects an estimated 71 million people globally according to WHO estimates. The use rates also reflect significant advancements made over recent years towards curing this previously challenging-to-treat condition.

Conclusion

Both Harvoni and Mavyret have profoundly impacted the treatment landscape for Hepatitis c, with numerous clinical studies showing high cure rates. These drugs are sometimes used in combination with other antivirals depending on the patient's viral genotype and previous treatment history. Both medications work by inhibiting enzymes necessary for the replication of Hepatitis C virus.

Harvoni is a fixed-dose combination drug that includes ledipasvir and sofosbuvir, usually prescribed as a once-daily pill for 12 to 24 weeks. Mavyret, meanwhile, contains glecaprevir and pibrentasvir – it also requires a shorter duration of therapy (8-16 weeks) which can be an advantage in terms of adherence.

Both Harvoni and Mavyret are available in generic forms providing cost savings especially for out-of-pocket payers. The onset of their effects may not be immediately noticeable as they act at a molecular level to inhibit viral replication over time.

In terms of side effects, both drugs are well-tolerated although minor differences exist; fatigue and headache being more common with Harvoni while nausea is more commonly reported with Mavyret. Regardless of these side effect profiles, patients must monitor their condition closely when starting treatment due to potential risks such as reactivation of Hepatitis b or liver complications.